Últimas noticias sobre CytomX Therapeutics (NASDAQ:CTMX) Bolsa

CytomX Therapeutics

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Inc

HC Wainwright &amp; Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) from Neutral to Neutral.

News

Reiteration

Analyst Ratings

ATRA

HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

WIIM

United Airlines shares are trading higher after the company reported better-than-expected Q4 financial results.

IBKR

Interactive Brokers shares are trading higher following better-than-expected Q4 financial results.

Citigroup analyst Christopher Allen maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Neutral and raises the price target from $80 to $85.

Price Target

SCHW

Citigroup Maintains Neutral on Charles Schwab, Raises Price Target to $85

The Offering is expected to close on or about January 23, 2025, subject to the satisfaction of customary closing conditions.&nbsp;

MCTR

CTRL Group Prices $8M Initial Public Offering Of 2M Common Shares At $4/Share

RVSN

Rail Vision shares are trading higher after the company announced a binding MoU with Sujan Ventures to introduce its safety systems to the Indian railway market.

FCEL

FuelCell Energy shares are trading higher after the company announced plans to build a 7.4 MW fuel cell power plant in Hartford, Connecticut, expected to add over $160 million to its generation backlog.

HC Wainwright &amp; Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and raises the price target from $36 to $39.

AVBP

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $39

ALLY

Ally Financial shares are trading higher after the company reported better-than-expected Q4 financial results and announced it will divest its credit card unit to CardWorks.

Deutsche Bank analyst Steve Powers maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Hold and lowers the price target from $80 to $78.

Deutsche Bank Maintains Hold on Estee Lauder Cos, Lowers Price Target to $78

Financing

IESC

IES Announced That It Has Amended And Restated Its Existing Credit And Security Agreement, Increasing The Commitment Amount Of The Revolving Credit Facility To $300M From $150M And Extending The Maturity Date To January 21, 2030 While Expanding The Size Of The Lending Group

Deutsche Bank analyst Steve Powers maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Buy and lowers the price target from $184 to $178.

Deutsche Bank Maintains Buy on PepsiCo, Lowers Price Target to $178

Macquarie analyst Tim Nollen maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $965 to $1150.

NFLX

Macquarie Maintains Outperform on Netflix, Raises Price Target to $1150

Deutsche Bank analyst Stephen Powers maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Hold and lowers the price target from $67 to $62.

MDLZ

Deutsche Bank Maintains Hold on Mondelez International, Lowers Price Target to $62

Rail Vision Announced The Signing Of A Binding Memorandum Of Understanding With Sujan Ventures, A Division Of The Esteemed Sujan Group To The Indian Rail Industry

Northland Capital Markets analyst Michael Latimore maintains Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) with a Outperform and raises the price target from $13 to $18.

GRRR

Northland Capital Markets Maintains Outperform on Gorilla Tech Gr, Raises Price Target to $18

Barclays analyst Jason Goldberg maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Underweight and raises the price target from $59 to $61.

ZION

Barclays Maintains Underweight on Zions Bancorp, Raises Price Target to $61

Northland Capital Markets analyst Gus Richard reiterates Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Outperform and raises the price target from $144 to $160.

Northland Capital Markets Reiterates Outperform on Seagate Tech Hldgs, Raises Price Target to $160

REKR

Rekor Systems' AI-Powered Scout Platform Secures Role In $13M New Jersey Public Safety Upgrade

AGYS

Agilysys shares are trading lower after the company reported worse-than-expected Q3 sales results and issued FY25 revenue guidance below estimates.

Piper Sandler lowered the firm's price target on CytomX Therapeutics (CTMX) to $3.25 from $3.50 and keeps an Overweight rating on the shares follow...

CytomX Therapeutics price target lowered to $3.25 from $3.50 at Piper Sandler

Warning: CTMX is at high risk of performing badly

Analysts fell to the sidelines weighing in on Xenetic Biosciences (XBIO – Research Report) and CytomX Therapeutics (CTMX – Research Report) with ne...

Wall Street Analysts Are Neutral on Top Healthcare Picks

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

JonesResearch analyst Soumit Roy keeps a Buy rating on CytomX Therapeutics (CTMX) with a $7 price target after the company announced the new drug a...

CytomX heading into 'major catalyst year,' says JonesResearch

"CytomX Therapeutics (CTMX) announced updated pipeline priorities and anticipated milestones for 2025. "Our top strategic objective for 2025 is the...

CytomX Therapeutics says focus on development of CRC treatment CX-2051 in FY25

Barclays analyst Peter Lawson maintained a Buy rating on CytomX Therapeutics (CTMX – Research Report) today and set a price target of $3.50. The co...

CytomX Therapeutics (CTMX) Gets a Buy from Barclays

Wedbush lowered the firm's price target on CytomX Therapeutics (CTMX) to $5 from $8 and keeps an Outperform rating on the shares. The firm notes Cy...

CytomX Therapeutics price target lowered to $5 from $8 at Wedbush

Wedbush analyst Robert Driscoll maintained a Buy rating on CytomX Therapeutics (CTMX – Research Report) today and set a price target of $5.00. The ...

CytomX Therapeutics (CTMX) Receives a Buy from Wedbush

CytomX falls after portfolio shakeup, job cuts

CANF

CAPR

CHRS

CTMX

CYCN

ENLV

HRTX

XBIO

Press Releases

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

Earnings

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Comments

CytomX Therapeutics

Noticias

Últimas noticias sobre CytomX Therapeutics (NASDAQ:CTMX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL